News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_c1ea3e9ebea44f1e00_myelodysplastic_syndrome.jpg)
In myelodysplastic syndrome, improved tool for predicting death after HCT
- Author:
- Mary Jo Dales
Key clinical point: A portion of patients with myelodysplastic syndrome in high- and very high–risk groups of the revised International Prognostic...
News
OTX015 dose for lymphoma narrowed in phase 1 study
- Author:
- Mary Jo Dales
Key clinical point: For lymphoma patients, a regimen has been determined for the small-molecule inhibitor OTX015 that was associated with...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_f0e9434bc4f9bdcd19_Blood cells.jpg)
LMWH doesn’t reduce late pregnancy loss in women with thrombophilias
- Author:
- Mary Jo Dales
Prophylactic-dose low molecular weight heparin, with or without aspirin, did not reduce the risk of pregnancy loss in women with inherited...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_7bf12d536070350d8a_EBUS.jpg)
CHEST issues guidelines on EBUS-TBNA
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_0c3b688209aac4f83a_FDA_icon.jpg)
Idelalisib use halted in six combo therapy trials, FDA announces
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_27bf6511d2f132a865_leukemia_acutelymphoblastic.jpg)
Guidelines on asparaginase hypersensitivity and silent inactivation in ALL
- Author:
- Mary Jo Dales
The recommendations address therapeutic drug monitoring through serum asparaginase level assessment, indications for switching asparaginase...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_27bf6511d2f132a865_MultipleMyeloma.jpg)
HIV drug may overcome proteasome-inhibitor resistance in multiple myeloma
- Author:
- Mary Jo Dales
Key clinical point: Adding HIV protease inhibitors to established combinations of proteasome inhibitors may improve outcomes in patients with...
News
Follicular lymphoma: Quantitative PET/CT measures for detecting bone marrow involvement
- Author:
- Mary Jo Dales
Key clinical point: Measuring the mean standardized uptake value of 18fluorodeoxyglucose in the bone marrow of patients with follicular lymphoma...
News
Generic sildenafil approved for erectile dysfunction
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_fc0eba158388ffa97e_CLL_Leukemia_3.jpg)
Ibrutinib approved as first-line therapy for all CLL patients
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_a77ad30c26ece63dd3_DNA_3.jpg)
Novel test detects low levels of residual CML
- Author:
- Mary Jo Dales
Key clinical point: A novel test may predict which CML patients in remission can safely stop TKI therapy. Major finding: Digital PCR for BCR-ABL1...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_0f8c24a_Majhail_Navneet_CLEVELAND.jpg)
Medicare to cover HSCT in approved clinical trials for myeloma, myelofibrosis, sickle cell disease
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_20724fd_Kalyacio_Matt Cleveland.jpg)
Consensus document issued on hematology research priorities for Europe
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_f13dba2_fda_icon2.jpg)
Ofatumumab approved for extended treatment of CLL patients in complete or partial response
- Author:
- Mary Jo Dales
Video
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/Screenshot_1_34.jpg)
Venetoclax gets 79% overall response rate in high-risk CLL
- Author:
- Mary Jo Dales